Inclusion Criteria:

          -  Histologically documented, locally advanced or recurrent (stage IIIb and not amenable
             to combined modality treatment) or metastatic (stage IV) non-small cell lung cancer,
             anti-cancer treatment naiive

          -  EGFR exon 19 deletion or exon 21 L858R.

          -  Bim deletion by realtime PCR, or low abundance for EGFR mutation, for 19Del less than
             4.9%, for L858R less than 9.5%.

          -  ECOG performance status of ≤ 1.

          -  Patients must have measurable disease according to the RECIST (version 1.1) criteria.

          -  Life expectancy of at least 12 weeks

          -  Written (signed) informed Consent to participate in the study.

          -  Adequate organ function as defined by the following criteria:

        Liver function: SGOT (AST) and SGPT (ALT) ≤ 2.5 X ULN in the absence of liver metastases or
        up to 5 X ULN in case of liver metastases. Total bilirubin ≤ 1.5ULN.

        Bone marrow function: Granulocyte count ≥ 1,500/mm3 and platelet count ≥100,000/mm3 and
        hemoglobin ≥90g/dl.

        Renal function: serum creatinine ≤ 1.5 ULN or creatinine clearance ≥ 60 ml/min. (based on
        modified Cockcroft-Gault formula).

          -  For all females of childbearing potential a negative serum/urine pregnancy test must
             be obtained within 48 hours before enrollment. Postmenopausal women must have been
             amenorrhoeic for at least 12 months to be considered of non-childbearing potential.

        Exclusion Criteria:

          -  Patients with prior chemotherapy or systemic anti-cancer therapy including target
             therapy targeting HER family members (such as erlotinib, gefitinib, cetuximab,
             trastuzumab, etc). Previous adjuvant or neo-adjuvant treatment for non-metastatic
             disease is permitted if completed ≥ 6 months before the enrollments.

          -  Patients with history of any other malignancies within 5 years (except for adequately
             treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).

          -  Patients who have brain metastasis or spinal cord compression. It is permitted if the
             patient has been treated with surgery and/or radiation with evidence of stable disease
             for at least 4 weeks.

          -  Patients who are at risk (in the investigator's opinion) of transmitting human
             immunodeficiency virus (HIV) through blood or other body fluids.

          -  lactating women

          -  Sexually active males and females (of childbearing potential) unwilling to practice
             contraception during the study.

          -  Unwilling to write informed consent to participate in the study or unwilling to
             receive follow-up

          -  Tumor invade big vessels or close to big vessels (less than 5mm)

          -  Obvious cavity or necrosis formed in the tumor, Uncontrolled hypertension, Myocardial
             ischemia or infarction more than stage II, cardiac insufficiency. Abnormal coagulation
             (INR>1.5 or PT>ULN+4, or APTT>1.5 ULN), bleeding tendency or receiving coagulation
             therapy

          -  Hemoptysis, more than 2.5ml daily

          -  Thrombosis in 12 months, including pulmonary thrombosis, stoke, or deep venous
             thrombosis.

          -  Unhealed bone fracture or wound for long time